Knee Osteoarthritis
Conditions
Brief summary
This is a prospective, multi-centre, non comparative, post market clinical follow-up study involving orthopaedic surgeons skilled in TKA and experienced implanting the devices included in this study.
Detailed description
The objectives of the study are to document the implant survivorship and clinical outcomes data for the Persona fixed bearing implants used in primary total knee arthroplasty (TKA). The study will include a maximum of 20 centres and up to 1000 implanted knees. Each centre may enrol up to a maximum of 100 implanted knees to permit assessment of the consistency of outcomes across a variety of investigators and clinical settings.
Interventions
DEVICEPersona fixed bearing knee system (All patients will receive Persona fixed bearing knee system)
Sponsors
Zimmer Biomet
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* Age 18 to 80 years old, inclusive * Qualifies for a primary TKA based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following: 1. Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis. 2. Collagen disorders and/ or avascular necrosis of femoral condyle. 3. Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy. 4. Moderate valgus, varus or flexion deformities. 5. The salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee. * Participated in a study-related informed consent process. * Willing and able to provide written informed consent by signing and dating the IRB/EC approved informed consent form. * Willing and able to complete scheduled study procedures and follow-up evaluations. * Independent of study participation, patient is a candidate for commercially available Persona fixed bearing knee system implanted in accordance with product labelling.
Exclusion criteria
* Currently participating in any other surgical intervention studies or pain management studies. * Previous history of infection in the affected joint and/or other local/systemic infection that may affect the prosthetic joint. * Insufficient bone stock on femoral or tibial surfaces/ * Skeletal immaturity * Neuropathic arthropathy * Any loss of musculature or neuromuscular disease that compromises the affected limb. * Stable, painless arthrodesis in a satisfactory functional position. * Severe instability secondary to the absence of collateral ligament integrity. * Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin. * Known or suspected sensitivity or allergy to one or more of the implant materials. * Pregnant or considered a member of a protected population (e.g. prisoner, mentally incompetent, etc.) * Previously received partial or total knee arthroplasty for the ipsilateral knee.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Implant Survivorship | Up to 5 years post surgery | Implant survivorship based on removal of the study device and will be summarized using Kaplan-Meier analysis |
| Adverse Events (Safety) | Up to 5 years post surgery | Safety based on incidence and frequency of adverse events |
| Clinical Performance | Up to 5 years post surgery | Clinical Performance measured by overall pain and function and qualify of life Measured using EQ5D questionnaire and Knee Society Score |
Countries
Australia, India, Japan, New Zealand, Singapore, South Korea
Outcome results
None listed